Zentalis Pharmaceuticals (ZNTL)

• Market cap: $261M
• 1 day: -0.81%
• 5 days: -5.41%
• 1 month: -9.61%
• 3 months: 45.06%
• 6 months: 162.14%
• Year to date: 167.88%
• 1 year: 182.31%
• 5 years: -92.96%
• 10 years: -84.18%
• Sector: Healthcare
• Industry: Biotechnology

About: Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Employees: 106